Evaluation of ondanstrone effect in reduction of negative symptoms in inpatients with schizophrenia disorder
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT2014031211071N2
- Lead Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 48
a diagnosis of schizophrenia according to DSM-IV-TR; an overall score of 50 or higher on the PANSS scale; 15 or higher negative score in PANSS scale; duration of at least 1 year from onset of the illness. Exclusion criteria: history of sensitivity to ondanstrone; serious medical illness; substance abuse or dependency in recent months; pregnancy; lactation; other simultaneous psychiatric disorders requiring medication; desire to homicide or suicide; having dementia and severe cognitive impairments not bound to schizophrenia; organic brain disorders such as seizure; severe mental retardation and Parkinsonism; consumption of oral antipsychotics during last month or long-acting Injectable forms within three months; Concomitant use of other drugs such as antidepressants; lithium which may interfere in treatment; drug-resistant schizophrenia disorder; lack of response to appropriate dosage and duration of Risperidone.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method egative sign. Timepoint: at the end of weeks 0 ,3 and 6. Method of measurement: PANSS questionnaire.
- Secondary Outcome Measures
Name Time Method Positive sign. Timepoint: at the end of weeks 0 ,3 and 6. Method of measurement: PANSS questionnaire.